Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- And PIK3CA- Wild-Type Metastatic Colorectal Cancer: The AGITG Randomised Phase II ICECREAM Study
Clinical Colorectal Cancer - United States
doi 10.1016/j.clcc.2018.06.002
Full Text
Open PDFAbstract
Available in full text
Date
December 1, 2018
Authors
Publisher
Elsevier BV